Summary
According to APO Research, The global Neurometabolic Disorders market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Neurometabolic Disorders is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Neurometabolic Disorders is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Neurometabolic Disorders is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Neurometabolic Disorders include Amicus, Amicus Therapeutics, Biomarin, Biosidus, Dong-A Socio Group, ExSAR Corporation, Genzyme, Greencross and Greenovation Biotech, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Neurometabolic Disorders, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurometabolic Disorders.
The Neurometabolic Disorders market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neurometabolic Disorders market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Neurometabolic Disorders Segment by Company
Amicus
Amicus Therapeutics
Biomarin
Biosidus
Dong-A Socio Group
ExSAR Corporation
Genzyme
Greencross
Greenovation Biotech
ISU Abxis
JCR Pharmaceuticals
Lixte Biotechnology
Neuraltus Pharmaceuticals
Pharming Group
Protalix
Protalix BioTherapeutics
Shire
UAB Proforma
Neurometabolic Disorders Segment by Type
Pompe Disease
Mucopolysaccharidosis VI
Gaucher’s Disease
Fabry Disease
Other
Neurometabolic Disorders Segment by Application
Oral
Parenteral
Neurometabolic Disorders Segment by Application
Oral
Parenteral
Neurometabolic Disorders Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurometabolic Disorders market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neurometabolic Disorders and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurometabolic Disorders.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Neurometabolic Disorders companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
- Preface
- Scope of Report
- Reasons for Doing This Study
- Research Methodology
- Research Process
- Data Source
- Secondary Sources
- Primary Sources
- Market Overview
- Product Definition
- Neurometabolic Disorders by Type
- Market Value Comparison by Type (2020 VS 2024 VS 2031)
- Pompe Disease
- Mucopolysaccharidosis VI
- Gaucher’s Disease
- Fabry Disease
- Other
- Neurometabolic Disorders by Application
- Market Value Comparison by Application (2020 VS 2024 VS 2031)
- Oral
- Parenteral
- Assumptions and Limitations
- Neurometabolic Disorders Breakdown Data by Type
- Global Neurometabolic Disorders Historic Market Size by Type (2020-2025)
- Global Neurometabolic Disorders Forecasted Market Size by Type (2026-2031)
- Neurometabolic Disorders Breakdown Data by Application
- Global Neurometabolic Disorders Historic Market Size by Application (2020-2025)
- Global Neurometabolic Disorders Forecasted Market Size by Application (2026-2031)
- Global Growth Trends
- Global Neurometabolic Disorders Market Perspective (2020-2031)
- Global Neurometabolic Disorders Growth Trends by Region
- Global Neurometabolic Disorders Market Size by Region: 2020 VS 2024 VS 2031
- Neurometabolic Disorders Historic Market Size by Region (2020-2025)
- Neurometabolic Disorders Forecasted Market Size by Region (2026-2031)
- Neurometabolic Disorders Market Dynamics
- Neurometabolic Disorders Industry Trends
- Neurometabolic Disorders Market Drivers
- Neurometabolic Disorders Market Challenges
- Neurometabolic Disorders Market Restraints
- Market Competitive Landscape by Players
- Global Top Neurometabolic Disorders Players by Revenue
- Global Top Neurometabolic Disorders Players by Revenue (2020-2025)
- Global Neurometabolic Disorders Revenue Market Share by Players (2020-2025)
- Global Neurometabolic Disorders Industry Players Ranking, 2023 VS 2024 VS 2025
- Global Key Players of Neurometabolic Disorders Head Office and Area Served
- Global Neurometabolic Disorders Players, Product Type & Application
- Global Neurometabolic Disorders Manufacturers Established Date
- Global Neurometabolic Disorders Market CR5 and HHI
- Global Players Mergers & Acquisition
- Global Top Neurometabolic Disorders Players by Revenue
- North America
- North America Neurometabolic Disorders Market Size (2020-2031)
- North America Neurometabolic Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031
- North America Neurometabolic Disorders Market Size by Country (2020-2025)
- North America Neurometabolic Disorders Market Size by Country (2026-2031)
- United States
- United States
- Canada
- Mexico
- Europe
- Europe Neurometabolic Disorders Market Size (2020-2031)
- Europe Neurometabolic Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031
- Europe Neurometabolic Disorders Market Size by Country (2020-2025)
- Europe Neurometabolic Disorders Market Size by Country (2026-2031)
- Germany
- France
- U.K.
- Italy
- Spain
- Russia
- Netherlands
- Nordic Countries
- Asia-Pacific
- Asia-Pacific Neurometabolic Disorders Market Size (2020-2031)
- Asia-Pacific Neurometabolic Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031
- Asia-Pacific Neurometabolic Disorders Market Size by Country (2020-2025)
- Asia-Pacific Neurometabolic Disorders Market Size by Country (2026-2031)
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Southeast Asia
- South America
- South America Neurometabolic Disorders Market Size (2020-2031)
- South America Neurometabolic Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031
- South America Neurometabolic Disorders Market Size by Country (2020-2025)
- South America Neurometabolic Disorders Market Size by Country (2026-2031)
- Brazil
- Argentina
- Chile
- Colombia
- Peru
- Middle East & Africa
- Middle East & Africa Neurometabolic Disorders Market Size (2020-2031)
- Middle East & Africa Neurometabolic Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031
- Middle East & Africa Neurometabolic Disorders Market Size by Country (2020-2025)
- Middle East & Africa Neurometabolic Disorders Market Size by Country (2026-2031)
- Saudi Arabia
- Israel
- United Arab Emirates
- Turkey
- Iran
- Egypt
- Players Profiled
- Amicus
- Amicus Company Information
- Amicus Business Overview
- Amicus Revenue in Neurometabolic Disorders Business (2020-2025)
- Amicus Neurometabolic Disorders Product Portfolio
- Amicus Recent Developments
- Amicus Therapeutics
- Amicus Therapeutics Company Information
- Amicus Therapeutics Business Overview
- Amicus Therapeutics Revenue in Neurometabolic Disorders Business (2020-2025)
- Amicus Therapeutics Neurometabolic Disorders Product Portfolio
- Amicus Therapeutics Recent Developments
- Biomarin
- Biomarin Company Information
- Biomarin Business Overview
- Biomarin Revenue in Neurometabolic Disorders Business (2020-2025)
- Biomarin Neurometabolic Disorders Product Portfolio
- Biomarin Recent Developments
- Biosidus
- Biosidus Company Information
- Biosidus Business Overview
- Biosidus Revenue in Neurometabolic Disorders Business (2020-2025)
- Biosidus Neurometabolic Disorders Product Portfolio
- Biosidus Recent Developments
- Dong-A Socio Group
- Dong-A Socio Group Company Information
- Dong-A Socio Group Business Overview
- Dong-A Socio Group Revenue in Neurometabolic Disorders Business (2020-2025)
- Dong-A Socio Group Neurometabolic Disorders Product Portfolio
- Dong-A Socio Group Recent Developments
- ExSAR Corporation
- ExSAR Corporation Company Information
- ExSAR Corporation Business Overview
- ExSAR Corporation Revenue in Neurometabolic Disorders Business (2020-2025)
- ExSAR Corporation Neurometabolic Disorders Product Portfolio
- ExSAR Corporation Recent Developments
- Genzyme
- Genzyme Company Information
- Genzyme Business Overview
- Genzyme Revenue in Neurometabolic Disorders Business (2020-2025)
- Genzyme Neurometabolic Disorders Product Portfolio
- Genzyme Recent Developments
- Greencross
- Greencross Company Information
- Greencross Business Overview
- Greencross Revenue in Neurometabolic Disorders Business (2020-2025)
- Greencross Neurometabolic Disorders Product Portfolio
- Greencross Recent Developments
- Greenovation Biotech
- Greenovation Biotech Company Information
- Greenovation Biotech Business Overview
- Greenovation Biotech Revenue in Neurometabolic Disorders Business (2020-2025)
- Greenovation Biotech Neurometabolic Disorders Product Portfolio
- Greenovation Biotech Recent Developments
- ISU Abxis
- ISU Abxis Company Information
- ISU Abxis Business Overview
- ISU Abxis Revenue in Neurometabolic Disorders Business (2020-2025)
- ISU Abxis Neurometabolic Disorders Product Portfolio
- ISU Abxis Recent Developments
- JCR Pharmaceuticals
- JCR Pharmaceuticals Company Information
- JCR Pharmaceuticals Business Overview
- JCR Pharmaceuticals Revenue in Neurometabolic Disorders Business (2020-2025)
- JCR Pharmaceuticals Neurometabolic Disorders Product Portfolio
- JCR Pharmaceuticals Recent Developments
- Lixte Biotechnology
- Lixte Biotechnology Company Information
- Lixte Biotechnology Business Overview
- Lixte Biotechnology Revenue in Neurometabolic Disorders Business (2020-2025)
- Lixte Biotechnology Neurometabolic Disorders Product Portfolio
- Lixte Biotechnology Recent Developments
- Neuraltus Pharmaceuticals
- Neuraltus Pharmaceuticals Company Information
- Neuraltus Pharmaceuticals Business Overview
- Neuraltus Pharmaceuticals Revenue in Neurometabolic Disorders Business (2020-2025)
- Neuraltus Pharmaceuticals Neurometabolic Disorders Product Portfolio
- Neuraltus Pharmaceuticals Recent Developments
- Pharming Group
- Pharming Group Company Information
- Pharming Group Business Overview
- Pharming Group Revenue in Neurometabolic Disorders Business (2020-2025)
- Pharming Group Neurometabolic Disorders Product Portfolio
- Pharming Group Recent Developments
- Protalix
- Protalix Company Information
- Protalix Business Overview
- Protalix Revenue in Neurometabolic Disorders Business (2020-2025)
- Protalix Neurometabolic Disorders Product Portfolio
- Protalix Recent Developments
- Protalix BioTherapeutics
- Protalix BioTherapeutics Company Information
- Protalix BioTherapeutics Business Overview
- Protalix BioTherapeutics Revenue in Neurometabolic Disorders Business (2020-2025)
- Protalix BioTherapeutics Neurometabolic Disorders Product Portfolio
- Protalix BioTherapeutics Recent Developments
- Shire
- Shire Company Information
- Shire Business Overview
- Shire Revenue in Neurometabolic Disorders Business (2020-2025)
- Shire Neurometabolic Disorders Product Portfolio
- Shire Recent Developments
- UAB Proforma
- UAB Proforma Company Information
- UAB Proforma Business Overview
- UAB Proforma Revenue in Neurometabolic Disorders Business (2020-2025)
- UAB Proforma Neurometabolic Disorders Product Portfolio
- UAB Proforma Recent Developments
- Amicus
- Report Conclusion
- Disclaimer
List of Tables
| Table 1 | :Secondary Sources |
| Table 2 | :Primary Sources |
| Table 3 | :Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million) |
| Table 4 | :Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million) |
| Table 5 | :Global Neurometabolic Disorders Market Size by Type (2020-2025) & (US$ Million) |
| Table 6 | :Global Neurometabolic Disorders Revenue Market Share by Type (2020-2025) |
| Table 7 | :Global Neurometabolic Disorders Forecasted Market Size by Type (2026-2031) & (US$ Million) |
| Table 8 | :Global Neurometabolic Disorders Revenue Market Share by Type (2026-2031) |
| Table 9 | :Global Neurometabolic Disorders Market Size by Application (2020-2025) & (US$ Million) |
| Table 10 | :Global Neurometabolic Disorders Revenue Market Share by Application (2020-2025) |
| Table 11 | :Global Neurometabolic Disorders Forecasted Market Size by Application (2026-2031) & (US$ Million) |
| Table 12 | :Global Neurometabolic Disorders Revenue Market Share by Application (2026-2031) |
| Table 13 | :Global Neurometabolic Disorders Market Size by Region (US$ Million): 2020 VS 2024 VS 2031 |
| Table 14 | :Global Neurometabolic Disorders Market Size by Region (2020-2025) & (US$ Million) |
| Table 15 | :Global Neurometabolic Disorders Market Share by Region (2020-2025) |
| Table 16 | :Global Neurometabolic Disorders Forecasted Market Size by Region (2026-2031) & (US$ Million) |
| Table 17 | :Global Neurometabolic Disorders Market Share by Region (2026-2031) |
| Table 18 | :Neurometabolic Disorders Industry Trends |
| Table 19 | :Neurometabolic Disorders Industry Drivers |
| Table 20 | :Neurometabolic Disorders Industry Opportunities and Challenges |
| Table 21 | :Neurometabolic Disorders Market Restraints |
| Table 22 | :Global Top Neurometabolic Disorders Players by Revenue (US$ Million) & (2020-2025) |
| Table 23 | :Global Neurometabolic Disorders Revenue Market Share by Players (2020-2025) |
| Table 24 | :Global Neurometabolic Disorders Industry Players Ranking, 2023 VS 2024 VS 2025 |
| Table 25 | :Global Key Players of Neurometabolic Disorders, Headquarters and Area Served |
| Table 26 | :Global Neurometabolic Disorders Players, Product Type & Application |
| Table 27 | :Global Players Market Concentration Ratio (CR5 and HHI) |
| Table 28 | :Global Neurometabolic Disorders by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024) |
| Table 29 | :Players Mergers & Acquisitions, Expansion Plans |
| Table 30 | :North America Neurometabolic Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million) |
| Table 31 | :North America Neurometabolic Disorders Market Size by Country (2020-2025) & (US$ Million) |
| Table 32 | :North America Neurometabolic Disorders Market Size by Country (2026-2031) & (US$ Million) |
| Table 33 | :Europe Neurometabolic Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million) |
| Table 34 | :Europe Neurometabolic Disorders Market Size by Country (2020-2025) & (US$ Million) |
| Table 35 | :Europe Neurometabolic Disorders Market Size by Country (2026-2031) & (US$ Million) |
| Table 36 | :Asia Pacific Neurometabolic Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million) |
| Table 37 | :Asia Pacific Neurometabolic Disorders Market Size by Region (2020-2025) & (US$ Million) |
| Table 38 | :Asia Pacific Neurometabolic Disorders Market Size by Country (2026-2031) & (US$ Million) |
| Table 39 | :South America Neurometabolic Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million) |
| Table 40 | :South America Neurometabolic Disorders Market Size by Country (2020-2025) & (US$ Million) |
| Table 41 | :South America Neurometabolic Disorders Market Size by Country (2026-2031) & (US$ Million) |
| Table 42 | :Middle East & Africa Neurometabolic Disorders Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million) |
| Table 43 | :Middle East & Africa Neurometabolic Disorders Market Size by Country (2020-2025) & (US$ Million) |
| Table 44 | :Middle East & Africa Neurometabolic Disorders Market Size by Country (2026-2031) & (US$ Million) |
| Table 45 | :Amicus Company Information |
| Table 46 | :Amicus Business Overview |
| Table 47 | :Amicus Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million) |
| Table 48 | :Amicus Neurometabolic Disorders Product Portfolio |
| Table 49 | :Amicus Recent Developments |
| Table 50 | :Amicus Therapeutics Company Information |
| Table 51 | :Amicus Therapeutics Business Overview |
| Table 52 | :Amicus Therapeutics Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million) |
| Table 53 | :Amicus Therapeutics Neurometabolic Disorders Product Portfolio |
| Table 54 | :Amicus Therapeutics Recent Developments |
| Table 55 | :Biomarin Company Information |
| Table 56 | :Biomarin Business Overview |
| Table 57 | :Biomarin Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million) |
| Table 58 | :Biomarin Neurometabolic Disorders Product Portfolio |
| Table 59 | :Biomarin Recent Developments |
| Table 60 | :Biosidus Company Information |
| Table 61 | :Biosidus Business Overview |
| Table 62 | :Biosidus Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million) |
| Table 63 | :Biosidus Neurometabolic Disorders Product Portfolio |
| Table 64 | :Biosidus Recent Developments |
| Table 65 | :Dong-A Socio Group Company Information |
| Table 66 | :Dong-A Socio Group Business Overview |
| Table 67 | :Dong-A Socio Group Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million) |
| Table 68 | :Dong-A Socio Group Neurometabolic Disorders Product Portfolio |
| Table 69 | :Dong-A Socio Group Recent Developments |
| Table 70 | :ExSAR Corporation Company Information |
| Table 71 | :ExSAR Corporation Business Overview |
| Table 72 | :ExSAR Corporation Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million) |
| Table 73 | :ExSAR Corporation Neurometabolic Disorders Product Portfolio |
| Table 74 | :ExSAR Corporation Recent Developments |
| Table 75 | :Genzyme Company Information |
| Table 76 | :Genzyme Business Overview |
| Table 77 | :Genzyme Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million) |
| Table 78 | :Genzyme Neurometabolic Disorders Product Portfolio |
| Table 79 | :Genzyme Recent Developments |
| Table 80 | :Greencross Company Information |
| Table 81 | :Greencross Business Overview |
| Table 82 | :Greencross Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million) |
| Table 83 | :Greencross Neurometabolic Disorders Product Portfolio |
| Table 84 | :Greencross Recent Developments |
| Table 85 | :Greenovation Biotech Company Information |
| Table 86 | :Greenovation Biotech Business Overview |
| Table 87 | :Greenovation Biotech Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million) |
| Table 88 | :Greenovation Biotech Neurometabolic Disorders Product Portfolio |
| Table 89 | :Greenovation Biotech Recent Developments |
| Table 90 | :ISU Abxis Company Information |
| Table 91 | :ISU Abxis Business Overview |
| Table 92 | :ISU Abxis Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million) |
| Table 93 | :ISU Abxis Neurometabolic Disorders Product Portfolio |
| Table 94 | :ISU Abxis Recent Developments |
| Table 95 | :JCR Pharmaceuticals Company Information |
| Table 96 | :JCR Pharmaceuticals Business Overview |
| Table 97 | :JCR Pharmaceuticals Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million) |
| Table 98 | :JCR Pharmaceuticals Neurometabolic Disorders Product Portfolio |
| Table 99 | :JCR Pharmaceuticals Recent Developments |
| Table 100 | :Lixte Biotechnology Company Information |
| Table 101 | :Lixte Biotechnology Business Overview |
| Table 102 | :Lixte Biotechnology Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million) |
| Table 103 | :Lixte Biotechnology Neurometabolic Disorders Product Portfolio |
| Table 104 | :Lixte Biotechnology Recent Developments |
| Table 105 | :Neuraltus Pharmaceuticals Company Information |
| Table 106 | :Neuraltus Pharmaceuticals Business Overview |
| Table 107 | :Neuraltus Pharmaceuticals Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million) |
| Table 108 | :Neuraltus Pharmaceuticals Neurometabolic Disorders Product Portfolio |
| Table 109 | :Neuraltus Pharmaceuticals Recent Developments |
| Table 110 | :Pharming Group Company Information |
| Table 111 | :Pharming Group Business Overview |
| Table 112 | :Pharming Group Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million) |
| Table 113 | :Pharming Group Neurometabolic Disorders Product Portfolio |
| Table 114 | :Pharming Group Recent Developments |
| Table 115 | :Protalix Company Information |
| Table 116 | :Protalix Business Overview |
| Table 117 | :Protalix Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million) |
| Table 118 | :Protalix Neurometabolic Disorders Product Portfolio |
| Table 119 | :Protalix Recent Developments |
| Table 120 | :Protalix BioTherapeutics Company Information |
| Table 121 | :Protalix BioTherapeutics Business Overview |
| Table 122 | :Protalix BioTherapeutics Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million) |
| Table 123 | :Protalix BioTherapeutics Neurometabolic Disorders Product Portfolio |
| Table 124 | :Protalix BioTherapeutics Recent Developments |
| Table 125 | :Shire Company Information |
| Table 126 | :Shire Business Overview |
| Table 127 | :Shire Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million) |
| Table 128 | :Shire Neurometabolic Disorders Product Portfolio |
| Table 129 | :Shire Recent Developments |
| Table 130 | :UAB Proforma Company Information |
| Table 131 | :UAB Proforma Business Overview |
| Table 132 | :UAB Proforma Revenue in Neurometabolic Disorders Business (2020-2025) & (US$ Million) |
| Table 133 | :UAB Proforma Neurometabolic Disorders Product Portfolio |
| Table 134 | :UAB Proforma Recent Developments |
| Table 135 | :Authors List of This Report |
List of Figures
| Figure 1 | :Research Methodology |
| Figure 2 | :Research Process |
| Figure 3 | :Key Executives Interviewed |
| Figure 4 | :Neurometabolic Disorders Product Image |
| Figure 5 | :Global Neurometabolic Disorders Market Size Comparison by Type (2025-2031) & (US$ Million) |
| Figure 6 | :Global Neurometabolic Disorders Market Share by Type: 2024 VS 2031 |
| Figure 7 | :Pompe Disease Product |
| Figure 8 | :Mucopolysaccharidosis VI Product |
| Figure 9 | :Gaucher’s Disease Product |
| Figure 10 | :Fabry Disease Product |
| Figure 11 | :Other Product |
| Figure 12 | :Global Neurometabolic Disorders Market Size by Application (2025-2031) & (US$ Million) |
| Figure 13 | :Global Neurometabolic Disorders Market Share by Application: 2024 VS 2031 |
| Figure 14 | :Oral Product |
| Figure 15 | :Parenteral Product |
| Figure 16 | :Global Neurometabolic Disorders Market Size (US$ Million), Year-over-Year: 2020-2031 |
| Figure 17 | :Global Neurometabolic Disorders Market Size, (US$ Million), 2020 VS 2024 VS 2031 |
| Figure 18 | :Global Neurometabolic Disorders Market Share by Region: 2024 VS 2031 |
| Figure 19 | :Global Neurometabolic Disorders Market Share by Players in 2024 |
| Figure 20 | :Global Neurometabolic Disorders Manufacturers Established Date |
| Figure 21 | :Global Top 5 and 10 Neurometabolic Disorders Players Market Share by Revenue in 2024 |
| Figure 22 | :Players Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024 |
| Figure 23 | :North America Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 24 | :North America Neurometabolic Disorders Market Share by Country (2020-2031) |
| Figure 25 | :United States Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 26 | :Canada Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 27 | :Mexico Neurometabolic Disorders Market Share by Country (2020-2031) |
| Figure 28 | :Europe Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 29 | :Europe Neurometabolic Disorders Market Share by Country (2020-2031) |
| Figure 30 | :Germany Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 31 | :France Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 32 | :U.K. Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 33 | :Italy Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 34 | :Spain Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 35 | :Russia Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 36 | :Netherlands Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 37 | :Nordic Countries Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 38 | :Asia-Pacific Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 39 | :Asia-Pacific Neurometabolic Disorders Market Share by Country (2020-2031) |
| Figure 40 | :China Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 41 | :Japan Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 42 | :South Korea Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 43 | :India Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 44 | :India Neurometabolic Disorders Market Share by Country (2020-2031) |
| Figure 45 | :Australia Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 46 | :China Taiwan Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 47 | :Southeast Asia Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 48 | :South America Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 49 | :South America Neurometabolic Disorders Market Share by Country (2020-2031) |
| Figure 50 | :Brazil Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 51 | :Argentina Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 52 | :Chile Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 53 | :Colombia Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 54 | :Peru Neurometabolic Disorders Market Size YoY Growth (2020-2031) & (US$ Million) |
| Figure 55 | :Amicus Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025) |
| Figure 56 | :Amicus Therapeutics Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025) |
| Figure 57 | :Biomarin Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025) |
| Figure 58 | :Biosidus Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025) |
| Figure 59 | :Dong-A Socio Group Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025) |
| Figure 60 | :ExSAR Corporation Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025) |
| Figure 61 | :Genzyme Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025) |
| Figure 62 | :Greencross Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025) |
| Figure 63 | :Greenovation Biotech Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025) |
| Figure 64 | :ISU Abxis Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025) |
| Figure 65 | :JCR Pharmaceuticals Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025) |
| Figure 66 | :Lixte Biotechnology Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025) |
| Figure 67 | :Neuraltus Pharmaceuticals Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025) |
| Figure 68 | :Pharming Group Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025) |
| Figure 69 | :Protalix Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025) |
| Figure 70 | :Protalix BioTherapeutics Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025) |
| Figure 71 | :Shire Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025) |
| Figure 72 | :UAB Proforma Revenue Growth Rate in Neurometabolic Disorders Business (2020-2025) |
Request a Sample
Sample excerpt is intended to facilitate an informed purchase decision. Its purpose is not to offer free information or act as a substitute for the comprehensive product. In order to tailor the sample to your specific requirements, we will reach out to you to gather more details about your criteria.

Pharma & Healthcare
Neurometabolic Disorders Industry Research Report 2025
Pages: 134
Complete Your Request
Customer reviews
- 0 out of 5
- 0 Reviews
5
4
3
2
1
No Rating Review Exist.
Write Review
Suggested Report
View MoreNo data found.